Hi, everyone. My name is Maury Raycroft, and I am one of the biotech analysts at Jefferies. I would like to welcome the team from Adlai Nortye. We have Chris Liu, Investor Relations, and Archie Tse, the CMO. Thanks so much for joining us today.
Thank you.
Thank you for having us.
We are going to do fireside chat format, so maybe for those who are new to the story, if you can give a one-minute intro to the company.
Sure. Maybe I'll start. I think at this point, most people know RASONQUE, and it's clear that RASONQUE has validated the RAS mechanism of action. Ultimately, however, we think that there's a lot of white space still in this space.
If you think about the label that it has, the FDA medical review, as well as talking to KOLs, there's still limitations on its safety tolerability, combinability, as well as efficacy, and that's where I think Adlai Nortye could differentiate, not only with one asset, but potentially with two assets.
We have our lead asset, AN9025, which is an oral small molecule pan-RAS inhibitor. We've seen, pre-clinically at least, a potentially wider therapeutic window, and it's a very potent asset. We also have a first-in-class pan-RAS inhibitor payload on an ADC called AN4035, so we're very excited about that.
Ultimately, we're hoping that we can prove that these assets are differentiated in 2027, where we're going to have two catalysts, in the first half for AN9025, and in the second half for AN4035.
Got it. Yeah, I think that's a great intro. For 9025, you mentioned the data first half of next year. Maybe talk more about that. How many patients will have received potentially active doses? How many will have had at least two scans? How will enrollment break down across the different tumor types for PDAC, lung cancer, and colorectal cancer?
Sure. Hi. Good morning. Archie Tse from Adlai Nortye. I'm the President, Head of Research & Development . Thanks for the opportunity to speak here. Yes, since we are the third pan-RAS(ON) tri-complex inhibitor company with global data, right? We want to make sure that at our data release, it's going to be a meaningful dataset.
We expect at least 50 subjects treated at the efficacious dose level, and covering the big three tumor types, PDAC, lung, and colorectal cancer, but probably predominantly PDAC. So far, the enrollment is half and half, U.S. patient and Chinese patients. That number may shift a little bit, but I think that's around the breakdown.
To that end about scans, we're hopeful that we'll have the majority of patients with two or more scans.
Got it. Okay. For second-line PDAC, what response rate and Grade 3 adverse event rates would you consider differentiated versus daraxonrasib?
Right. We consider a delta of 10 points or so in terms of ORR. I think that would be meaningful clinically. In terms of safety profile, in addition to the high-grade AEs, like you mentioned, I think there are other aspects that's worth taking into account, and that includes AE leading to dose interruptions and dose reductions, which would impact on the overall dose intensity. Also, some of the quality of life relevant AEs, including even like Grade 2 diarrhea and stomatitis.
You want to see differences on those,
Correct.
As well? Okay. For the lines of therapy for these patients, anything more on that that you are saying for how many will be second-line versus other lines?
Right. From our datasets, we expect primarily second-plus line PDAC patients. Initially, we have a lot of patients in both China and U.S., but since the approval, we probably expect more of those patients coming from China.
Got it. Okay. For this update, you will have about half the patients from U.S., half the patients from China. Do you expect a difference there between the regions as it relates to PK and potentially safety? Ultimately, who controls the timing of ASK Pharm's data disclosure as well?
Yes. We are leading the first-in-human study, so we do not expect to see a regional difference in terms of the PKs and safety. That is our expectation. We do not expect that.
Just to clarify, on the 50/50 split, that is currently.
Right.
I think as time goes on and China tends to enroll a bit quicker, that dynamic might shift.
Got it. Okay. But for first half of next year, you anticipate most of the patients we are going to be looking at are going to be 50/50 split.
I think it will be more like 60/40 or 70/30 China/U.S.
Okay. Understood. Wondering if you've reached an MTD yet. If activity is already evident, how do you decide between continuing escalation and selecting a lower dose with a wider therapeutic window?
Yeah, so we have not reached MTD yet. We're still going up on the dose. We are also very happy with the profile that we've seen so far in terms of safety, PK, and efficacy. So we actually started some backfilling at multiple dose levels below the MTD. We have not seen MTD yet.
Okay. What level of exposure do you believe is required for meaningful RAS inhibition in humans? Will the update include PD measures such as the DUSP6 or ctDNA to show that you've reached it?
Yeah, so we have done pretty extensive preclinical modeling simulations, a lot head-to-head with Darax. So we have a pretty good way to estimate what is the equivalent exposure of AN9025 that is equivalent to Darax at 300 dose. So, we will take a look at the clinically observed PK from our dataset. At the same time, we also have collected some PD with cell-free DNA data as well.
Got it. I guess any more specifics you are saying on dosing? If you have not reached the MTD yet, are you still going higher with dosing or any other context on that?
Yeah, so we have not reached MTD, but the fact that we already opened backfill, then you expect we would have seen something.
Okay. Understood. For AN9025, is exposure dose proportional or does it begin to plateau? Separately, how much accumulation do you see at steady state with QD dosing?
Right. We are probably not in a position to disclose any PK-related data yet, but based on our projected half-life of around 40 hours compared to 12 hours with Darax, we do expect to see some accumulation.
Got it. Okay. With your half-life, I guess, could that lead to delayed or cumulative toxicities beyond the DLT window?
Yeah, I think that's a great question. With Darax, most AE you see would be within sort of like two weeks, right? With a longer half-life associated with AN9025, it may be a little bit longer than that, but with our 21 day DLT observation, we expect that should be able to capture the vast majority of the AEs.
Got it. If AN9025 ultimately has a similar efficacy ceiling to daraxonrasib, the differentiation may depend on safety. What should investors look for in the first dataset to assess that?
Yeah, I think it's no question that Darax is a forerunner and a breakthrough, but we know the safety and tolerability is not necessarily a walk in the park, right? So there's still a lot of room for improvement, especially on safety. As mentioned, we'll take a look at, in addition to high-grade AEs, the relevant on-target tox like rash, GI tox, also dose intensity, dose interruptions, reduction. I think these are all important.
Maury, I would say that an important thing to garner from all this information is also combinability, right? Ultimately, I think where the space is going is in these combination regimens potentially. I think that's where we can have a differentiated profile, be able to combine either with more agents or in a better fashion. I think that will also be a differentiating factor.
With QD monotherapy, for efficacy, you mentioned the 10% delta. For safety, what would you want to see that would convince you that you can combine with other agents safely, potentially more safely than daraxonrasib?
Yeah. I think non-overlapping tox, right? Or if there is overlapping tox, especially GI tox, I think that that has to be meaningfully reduced, because some of the agents that we're going to be combining probably have some GI tox, especially like modified FOLFIRINOX.
Right. Okay. You're testing the daily dosing versus the weekly dosing strategy. Maybe talk more about that. What would weekly dosing need to show to displace daily dosing? Would it be similar efficacy with better tolerability or deeper responses enabled by a higher peak dose? How many weekly patients could be included in the initial data update?
Right. Just to remind people, our preclinical results show that with the daily dosing, our molecule could potentially be differentiated already, but with the QW, we can even further widen the therapeutic window. We saw that when the total weekly dose added up to be the same, efficacy turned out to be the same regardless of whether you give the drug once a day or twice a week or once a week.
We are going to use that as a first pass screen to test whether the QW hypothesis is right. Let's say if the total weekly dose of the QW schedule exceeded at the MTD, exceeded the total weekly dose of the QD MTD, then I think that would support the preclinical data to move forward. Otherwise, it would just be focusing on the QD dosing.
In fact, we are quite happy with the profile that we have seen so far with the QD dosing, so that is why we said that we are actually going to go ahead and initiate some of this combo study with the QD dosing without waiting for the QW dosing, for example, like in first-line PDAC combination.
Yeah. As a reminder, we do have, from what we can tell, the most potent pan-RAS inhibitor in the pipeline. I think from what we have seen with other pan-RAS inhibitors that happen to be more potent than RASONQUE,
We have seen this trend of a numerical increase in efficacy as well as a numerically better safety profile, including GI tox, including a lessened severity of rash. I think if we take a look at our asset and how potent it is, I think we can hopefully follow that trend through.
Got it. With the greater potency, you get more flexibility with dosing. With the weekly dosing, do you think the efficacy, is it driven by Cmax or Ctrough?
Yeah, I think that's a great question. The answer is nobody knows because no other company is actually testing more than one schedule, right? There's no way to differentiate whether either efficacy or safety is Cmax or Ctrough driven.
We are the only company who actually able to answer that question because we're actually testing different dosing schedule, potentially have the same total dose, right, but different schedule, so that you can really differentiate those parameters.
Are you predicting more on how efficacy and safety could play out with the weekly, some of the benefit there with giving the patients the break on safety? How do you think about that?
Right. The QW is based on the hypothesis that normal tissues are less addicted to the RAS signaling pathway. If you give them a holiday, they may recover faster from the on-target toxicity from RAS inhibitions, unlike tumor, which is very addicted to the RAS, and they tend to die. That's the hypothesis. So far, our preclinical data supports that.
Got it. Okay. Talk about the ultimate strategy here. I guess, would it be for QD, for monotherapy, and chemo or IO combinations, and then with weekly, you would reserve that for combinations with more overlapping toxicity, such as EGFR antibodies?
Yeah, I think that would be a data-driven decision. We said that we're going to actually go ahead with the QD dosing in first-line combo PDAC. If the QW turnouts to be better later, we would explore that as well. We're not going to wait until we have the QW data to make a decision which one to move forward.
Got it. Okay. Do you plan to start development in frontline PDAC before the weekly arm matures? If so, what gives you enough confidence to move forward for that frontline PDAC setting?
Right. Like I said, we're happy with the profile we've seen so far that believing that it would give us a good combinability with chemotherapy.
Got it. Okay. Anything more on timing for that then?
Yeah. We're targeting towards the end of this year or early next year to start that first line.
Got it.
I just want to also highlight that it's important to note that, as far as we know, we're the only pan-RAS inhibitor that's looking to combine with modified FOLFIRINOX as even a possibility. So I think that should also suggest that we believe our potential profile could be amenable to that.
Got it. For frontline PDAC, will you test both gemcitabine and nab-paclitaxel and the modified FOLFIRINOX? What will determine the preferred backbone, and would combo dosing begin below the monotherapy dose?
Right. We put a lot of thoughts on picking the chemotherapy backbone doses, and without going into detail, our strategy align quite well with a lot of the KOL we are thinking.
Got it. Okay. When could phase III studies in pancreatic or lung cancer begin, and what would need to be established by year-end 2027 to advance in both settings? In what scenario would you pick weekly dosing for registrational study?
Right. I think that also would be a data-driven decision, but we are targeting if we can at least start preparing for registration path towards the end of next year.
Okay. I guess what would you want to see in the data to make that decision to move forward with weekly?
I think it would be combinability with the chemotherapy backbones.
Okay.
For non-small cell lung cancer, because you mentioned that indication, I think for now that's too early to tell.
Got it. Okay. How do you think about U.S. phase III enrollment given daraxonrasib uptake, and how are you planning to mitigate that risk?
Yeah. That's anticipated, right? We expect U.S. enrollments probably will be somewhat impacted. That's why we are already opening up some non-U.S. sites for our phase I, including Canada, Australia, and E.U.
Got it. Okay. Based on your positioning in the evolving landscape, what is your base case expectation for the phase III primary endpoint in PDAC? Could PFS support approval, or do you expect FDA to require OS?
Yeah. I think that's, of course, this is something you have to discuss with the agency. We are cognizant about some of the endpoints that our peers are proposing, right? So, like ORR and PFS potential accelerated approval endpoints. We'll be following and watching that very closely.
Got it. Okay. For lung cancer, it sounds like pancreatic's a priority. For lung cancer, maybe talk a little bit more about the strategy there. Is it going to be monotherapy in second line, or is the preference to get IO and combo in front line?
Yeah. I think front line is what we will be focusing in various combinations, including checkpoint inhibitors.
Okay. How do you rank or prioritize the major combo opportunities when considering IO and lung cancer, EGFR inhibition, and colorectal cancer? Then there is also data coming out on PRMT5 inhibition as well.
I think we are open to all those. In terms of prioritization, first line PDAC, of course. Then I think lung first line, we would most likely end up doing that. Regarding colorectal cancer, I think that is going to be also a especially safety data-driven decision, right? How much skin rash you see, and whether it can be combined with EGFR.
We would take that very carefully decision because we also have another assets, right? The ADC, it is more specific for colorectal cancer, EGFR combination. The PRMT5, I think that is, we believe that is a valid mechanism. So, we definitely open for that as well.
Got it. Okay. In the last couple minutes, let us shift gears, talk about the ADC, where there is a lot of interest as well. For that clinical study, without a CEACAM5 enrollment cutoff, how will you determine whether activity is CEACAM5 dependent, and do you predict H-score circulating CEA or intratumor payload levels will provide the most useful information there?
Right. So, for the big three tumor types, colorectal, PDAC, and lung, we are not requiring any kind of CEACAM5 cutoff. But other than that, we need a elevated CEA level, just circulating, just a very simple tumor marker that being done routinely in the clinic.
We would not prospectively screen for H-score, but we will retrospectively look at CEACAM5 expression. In our preclinical study so far, in colorectal, it is universally high, so we do not believe that we actually need to screen patient based on that.
Got it. That makes sense. What clinical evidence could confirm that the payload remains concentrated in the tumor rather than circulating systemically? Maybe comment on expectations for free payload, PK paired biopsies, or the absence of systemic tox, like rash.
Right. I think this is probably, we'll be relying on clinical data. The protocol allows optional biopsies to look at PD markers and potentially even payload in the tumor. But I think that's, it's a hit-and-miss things for pre and post biopsy. We expect if the on-target toxicity will be reduced or will become very much manageable, I think that will be a good sign.
Got it. Just kind of a theoretical question. Why should AN4035 plus cetuximab outperform systemic pan-RAS inhibition plus EGFR blockade? Is the advantage full dose cetuximab, lower systemic RAS exposure, or deeper intratumor RAS inhibition? How predictive is the NHP tox for humans?
We're going to have a oral presentation at the Triple Meeting tomorrow. We're going to share some of those data. Yes, stay tuned for that. I think so far the data looks very encouraging.
Got it. Okay. You are heading to Triple Meeting pretty soon for that then.
Yes. Have a flight tonight.
Given the high DAR for AN4035, what have you observed regarding aggregation and deconjugation in human plasma, and could the CEACAM5 antigen sink materially affect dosing?
So far, the developability is great. It is surprisingly for a very complex molecule, right? The DAR, and we have seen very good stability in conjugation site, the linker, and the DAR as well. What was the last part? I forgot the,
Just with the CEACAM5 antigen sink.
The sink. Okay.
Yeah.
We did look at that preclinically, and that does not seem to be affected by either the target-mediated disposition or soluble CEA level.
Got it. Okay. We are pretty much out of time. Maybe in closing, if you want to talk about cash runway, and then you mentioned the two big catalysts for next year. Anything else you want to highlight as far as the catalysts during those?
Yeah, sure. We ended the first half of 2026 with about $232 million in cash and equivalents. That'll get us through our two key catalysts next year in 2027, in the first half for AN9025, as well as in the second half for AN4035, and through 2028. In terms of other catalysts, I would say just stay tuned for our two major catalysts. I think those are going to be the wholesome data readouts that everyone's looking forward to seeing.
Got it. Okay. Archie, Chris, thanks so much for joining us today.
Thank you.